Cantor Fitzgerald downgraded Allakos from Overweight to Neutral
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/17/2024 | $6.00 → $1.50 | Buy → Hold | Jefferies |
| 1/16/2024 | Overweight → Neutral | Cantor Fitzgerald | |
| 12/18/2023 | Mkt Perform → Outperform | William Blair | |
| 12/8/2023 | $9.00 → $6.00 | Buy | Jefferies |
| 9/27/2023 | $11.00 | Mkt Outperform | JMP Securities |
| 5/12/2023 | $6.00 → $9.00 | Hold → Buy | Jefferies |
| 3/7/2023 | $22.00 | Overweight | Piper Sandler |
| 9/12/2022 | $2.00 | Neutral → Underperform | SMBC Nikko |
4 - Allakos Inc. (0001564824) (Issuer)
4 - Allakos Inc. (0001564824) (Issuer)
4 - Allakos Inc. (0001564824) (Issuer)
SAN CARLOS, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. ("Allakos") (NASDAQ:ALLK), a biotechnology company that has been developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today announced it has entered into a definitive merger agreement (the "Merger Agreement") whereby Concentra Biosciences, LLC ( "Concentra") will acquire Allakos for $0.33 in cash per share of Allakos common stock ("Allakos Common Stock"). Allakos' Board of Directors has unanimously determined that the acquisition by Concentra is in the best interests of all Allakos shareholders and, following the unanimous recommendation of Allakos' Transaction Committee, has appro
SAN CARLOS, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (the "Company") (NASDAQ:ALLK), a biotechnology company that has been developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the fourth quarter ended December 31, 2024. Recent Allakos Events Reported topline data from the Phase 1 study of AK006 in patients with chronic spontaneous urticaria in January 2025.Announced in January 2025 that the Company was discontinuing further development of AK006, restructuring operations to reduce costs and exploring strategic alternatives. Cash Guidance Allakos ended the fourth qua
SOUTH SAN FRANCISCO, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc., a biotechnology company developing lysosomal targeting chimera (LYTAC)-based protein degradation therapies to eliminate disease at its source, today announced the appointment of Chin Lee, M.D., M.P.H., as its chief medical officer. Dr. Lee brings more than 20 years of clinical research and development experience, advancing therapies from early stage to commercialization. He will oversee the company's clinical, nonclinical and regulatory functions and the advancement of its pipeline of LYTAC degraders. Lycia's proprietary LYTAC platform enables the rapid, deep and selective depletion of extracellular
10-K/A - Allakos Inc. (0001564824) (Filer)
SCHEDULE 13D/A - Allakos Inc. (0001564824) (Subject)
SC 14D9 - Allakos Inc. (0001564824) (Subject)
SOUTH SAN FRANCISCO, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc., a biotechnology company developing lysosomal targeting chimera (LYTAC)-based protein degradation therapies to eliminate disease at its source, today announced the appointment of Chin Lee, M.D., M.P.H., as its chief medical officer. Dr. Lee brings more than 20 years of clinical research and development experience, advancing therapies from early stage to commercialization. He will oversee the company's clinical, nonclinical and regulatory functions and the advancement of its pipeline of LYTAC degraders. Lycia's proprietary LYTAC platform enables the rapid, deep and selective depletion of extracellular
SAN CARLOS, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced the appointment of Neil Graham, M.D. to the Allakos board of directors. Dr. Graham was the Chief Medical Officer of Tiziana Life Sciences Limited and currently serves on the board of directors of Aslan Pharmaceuticals Limited, Pharmaxis Limited and Zura Bio Limited. Among other experiences, Dr. Graham was the Vice President of Strategic Program Direction, Immunology and Inflammation at Regeneron Ph
SAN CARLOS, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced the appointment of Rand Sutherland, M.D. and Dolca Thomas, M.D. to the Allakos board of directors. Dr. Sutherland was the Chief Executive Officer of Seeker Biologics, a privately-held company, and currently serves on the board of directors of Krystal Biotech, Inc. and Vanqua Bio, Inc. Among other experiences, Dr. Sutherland held senior roles developing therapeutics at Translate Bio, Inc. as well
– AK006 did not demonstrate therapeutic activity in CSU –– Allakos will discontinue further development of AK006, reduce workforce by 75% and explore strategic alternatives –– Management to host conference call and webcast today at 8:30 am E.T. – SAN CARLOS, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (Company) (NASDAQ:ALLK), today announced topline results from its phase 1 clinical trial of AK006 in chronic spontaneous urticaria (CSU). "While AK006 was well tolerated, we are disappointed that the preclinical inhibitory effects observed did not translate to clinical benefit in patients with CSU. As a result, the Company has decided to discontinue further clinical developme
Existing cash to fund planned ongoing operations into mid-2026AK006 is being tested in a comprehensive Phase 1 clinical program, including: ongoing single and multiple ascending dose trial in healthy volunteersa randomized, double-blind, placebo-controlled trial in patients with CSUa subcutaneous AK006 Phase 1 PK and bioavailability trial Management to host conference call and webcast today at 8:00 am E.T. SAN CARLOS, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the Company) (NASDAQ:ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today announced a restructuring to reduce costs and to focus on AK006 c
– Allakos plans not to pursue further development of lirentelimab; will focus on AK006 clinical development and additional preclinical programs – – Management to host conference call and webcast today at 8:00 am E.T. – SAN CARLOS, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the "Company") (NASDAQ:ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today announced topline data from its phase 2 clinical trial in patients with atopic dermatitis (ATLAS) and from its Phase 2b clinical trial in patients with chronic spontaneous urticaria (MAVERICK). "We are disappointed that these trials did not m
Jefferies downgraded Allakos from Buy to Hold and set a new price target of $1.50 from $6.00 previously
Cantor Fitzgerald downgraded Allakos from Overweight to Neutral
William Blair upgraded Allakos from Mkt Perform to Outperform
SC 13G - Allakos Inc. (0001564824) (Subject)
SC 13G/A - Allakos Inc. (0001564824) (Subject)
SC 13G/A - Allakos Inc. (0001564824) (Subject)